Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma

Nathan D. Seligson, Achal Awasthi, Sherri Z. Millis, Brian K. Turpin, Christian Meyer, Anne Grand'Maison, David A. Liebner, John L. Hays, James L. Chen

Research output: Contribution to journalArticle

Abstract

Importance: Epithelioid hemangioendothelioma (EHE) is a rare, malignant vascular sarcoma characterized in most cases by a WWTR1-CAMTA1 fusion. The clinical course of EHE exhibits a dual nature. The condition is often indolent but can rapidly grow and metastasize unpredictably. No biomarkers to date are available to predict this phenotype. The hypothesis of this study was that better defining the genomic landscape of EHE using next-generation sequencing could offer additional therapies and insight into clinical outcomes. Objective: To characterize secondary EHE genomic alterations and their association with clinical outcomes. Design, Setting, and Participants: Multicenter, cross-sectional, retrospective study of next-generation sequencing results collected from participants diagnosed with EHE. Data were abstracted between May 1, 2013, and May 31, 2019. This analysis was conducted from January through June 2019. Summary genomic data were provided by commercial genomic testing companies. Main Outcomes and Measures: Presence or absence of secondary pathogenic genomic variants and their association with disease stage and clinical features. Results: A total of 49 participants with EHE were assessed for the presence or absence of secondary genomic variants. Of these, 32 (65.3%) were female; the mean (SD) age at diagnosis was 49.9 (18.3) years (range, 11-81 years). In all, 46 participants (93.9%) had confirmed WWTR1-CAMTA1 fusion; 26 participants (57.1%) exhibited a pathogenic genomic variant secondary to the WWTR1-CAMTA1 fusion; and 9 participants (18.4%) exhibited potentially targetable genomic variants. Commonly altered genes included CDKN2A/B, RB1, APC, and FANCA. Participants older than 45 years at diagnosis had an increased prevalence of secondary genomic variants that was not statistically significant (65.6% vs 38.5%; difference, 27.1%; 95% CI, -3.5% to 58.0%; P = .16) and were more likely to have a clinically targetable variant (28.1% vs 0%; difference, 28.1%; 95% CI, 11.2%-40.2%; P = .03). In 14 participants with clinical data available, those with stage III/IV EHE were more likely to exhibit a secondary pathogenic genomic variant (80% vs 0%; difference, 80%; 95% CI, 55.2%-100%; P = .006). Participants with stage III/IV EHE were diagnosed at an older age (mean [SD] age, 54.6 [14.1] years vs 31.7 [16.0] years; P = .05) and had elevated WWTR1-CAMTA1 fusion expression that was not statistically significant (mean [SD] expression, 677 [706] copies vs 231 [213] copies; P = .20). Conclusions and Relevance: Although EHE exhibits few secondary genomic variants, presence of key secondary variants may be prognostic for aggressive EHE. Further research is needed to confirm this finding and determine whether more intensive upfront treatment is necessary for these patients.

Original languageEnglish (US)
Pages (from-to)e1912416
JournalJAMA Network Open
Volume2
Issue number10
DOIs
StatePublished - Oct 2 2019

Fingerprint

Epithelioid Hemangioendothelioma
p16 Genes
Sarcoma
Blood Vessels
Retrospective Studies
Cross-Sectional Studies
Biomarkers

Cite this

Seligson, N. D., Awasthi, A., Millis, S. Z., Turpin, B. K., Meyer, C., Grand'Maison, A., ... Chen, J. L. (2019). Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma. JAMA Network Open, 2(10), e1912416. https://doi.org/10.1001/jamanetworkopen.2019.12416

Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma. / Seligson, Nathan D.; Awasthi, Achal; Millis, Sherri Z.; Turpin, Brian K.; Meyer, Christian; Grand'Maison, Anne; Liebner, David A.; Hays, John L.; Chen, James L.

In: JAMA Network Open, Vol. 2, No. 10, 02.10.2019, p. e1912416.

Research output: Contribution to journalArticle

Seligson, ND, Awasthi, A, Millis, SZ, Turpin, BK, Meyer, C, Grand'Maison, A, Liebner, DA, Hays, JL & Chen, JL 2019, 'Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma', JAMA Network Open, vol. 2, no. 10, pp. e1912416. https://doi.org/10.1001/jamanetworkopen.2019.12416
Seligson, Nathan D. ; Awasthi, Achal ; Millis, Sherri Z. ; Turpin, Brian K. ; Meyer, Christian ; Grand'Maison, Anne ; Liebner, David A. ; Hays, John L. ; Chen, James L. / Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma. In: JAMA Network Open. 2019 ; Vol. 2, No. 10. pp. e1912416.
@article{abd3e7fad57248ceb7ea050fc3a8a0ca,
title = "Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma",
abstract = "Importance: Epithelioid hemangioendothelioma (EHE) is a rare, malignant vascular sarcoma characterized in most cases by a WWTR1-CAMTA1 fusion. The clinical course of EHE exhibits a dual nature. The condition is often indolent but can rapidly grow and metastasize unpredictably. No biomarkers to date are available to predict this phenotype. The hypothesis of this study was that better defining the genomic landscape of EHE using next-generation sequencing could offer additional therapies and insight into clinical outcomes. Objective: To characterize secondary EHE genomic alterations and their association with clinical outcomes. Design, Setting, and Participants: Multicenter, cross-sectional, retrospective study of next-generation sequencing results collected from participants diagnosed with EHE. Data were abstracted between May 1, 2013, and May 31, 2019. This analysis was conducted from January through June 2019. Summary genomic data were provided by commercial genomic testing companies. Main Outcomes and Measures: Presence or absence of secondary pathogenic genomic variants and their association with disease stage and clinical features. Results: A total of 49 participants with EHE were assessed for the presence or absence of secondary genomic variants. Of these, 32 (65.3{\%}) were female; the mean (SD) age at diagnosis was 49.9 (18.3) years (range, 11-81 years). In all, 46 participants (93.9{\%}) had confirmed WWTR1-CAMTA1 fusion; 26 participants (57.1{\%}) exhibited a pathogenic genomic variant secondary to the WWTR1-CAMTA1 fusion; and 9 participants (18.4{\%}) exhibited potentially targetable genomic variants. Commonly altered genes included CDKN2A/B, RB1, APC, and FANCA. Participants older than 45 years at diagnosis had an increased prevalence of secondary genomic variants that was not statistically significant (65.6{\%} vs 38.5{\%}; difference, 27.1{\%}; 95{\%} CI, -3.5{\%} to 58.0{\%}; P = .16) and were more likely to have a clinically targetable variant (28.1{\%} vs 0{\%}; difference, 28.1{\%}; 95{\%} CI, 11.2{\%}-40.2{\%}; P = .03). In 14 participants with clinical data available, those with stage III/IV EHE were more likely to exhibit a secondary pathogenic genomic variant (80{\%} vs 0{\%}; difference, 80{\%}; 95{\%} CI, 55.2{\%}-100{\%}; P = .006). Participants with stage III/IV EHE were diagnosed at an older age (mean [SD] age, 54.6 [14.1] years vs 31.7 [16.0] years; P = .05) and had elevated WWTR1-CAMTA1 fusion expression that was not statistically significant (mean [SD] expression, 677 [706] copies vs 231 [213] copies; P = .20). Conclusions and Relevance: Although EHE exhibits few secondary genomic variants, presence of key secondary variants may be prognostic for aggressive EHE. Further research is needed to confirm this finding and determine whether more intensive upfront treatment is necessary for these patients.",
author = "Seligson, {Nathan D.} and Achal Awasthi and Millis, {Sherri Z.} and Turpin, {Brian K.} and Christian Meyer and Anne Grand'Maison and Liebner, {David A.} and Hays, {John L.} and Chen, {James L.}",
year = "2019",
month = "10",
day = "2",
doi = "10.1001/jamanetworkopen.2019.12416",
language = "English (US)",
volume = "2",
pages = "e1912416",
journal = "JAMA network open",
issn = "2574-3805",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma

AU - Seligson, Nathan D.

AU - Awasthi, Achal

AU - Millis, Sherri Z.

AU - Turpin, Brian K.

AU - Meyer, Christian

AU - Grand'Maison, Anne

AU - Liebner, David A.

AU - Hays, John L.

AU - Chen, James L.

PY - 2019/10/2

Y1 - 2019/10/2

N2 - Importance: Epithelioid hemangioendothelioma (EHE) is a rare, malignant vascular sarcoma characterized in most cases by a WWTR1-CAMTA1 fusion. The clinical course of EHE exhibits a dual nature. The condition is often indolent but can rapidly grow and metastasize unpredictably. No biomarkers to date are available to predict this phenotype. The hypothesis of this study was that better defining the genomic landscape of EHE using next-generation sequencing could offer additional therapies and insight into clinical outcomes. Objective: To characterize secondary EHE genomic alterations and their association with clinical outcomes. Design, Setting, and Participants: Multicenter, cross-sectional, retrospective study of next-generation sequencing results collected from participants diagnosed with EHE. Data were abstracted between May 1, 2013, and May 31, 2019. This analysis was conducted from January through June 2019. Summary genomic data were provided by commercial genomic testing companies. Main Outcomes and Measures: Presence or absence of secondary pathogenic genomic variants and their association with disease stage and clinical features. Results: A total of 49 participants with EHE were assessed for the presence or absence of secondary genomic variants. Of these, 32 (65.3%) were female; the mean (SD) age at diagnosis was 49.9 (18.3) years (range, 11-81 years). In all, 46 participants (93.9%) had confirmed WWTR1-CAMTA1 fusion; 26 participants (57.1%) exhibited a pathogenic genomic variant secondary to the WWTR1-CAMTA1 fusion; and 9 participants (18.4%) exhibited potentially targetable genomic variants. Commonly altered genes included CDKN2A/B, RB1, APC, and FANCA. Participants older than 45 years at diagnosis had an increased prevalence of secondary genomic variants that was not statistically significant (65.6% vs 38.5%; difference, 27.1%; 95% CI, -3.5% to 58.0%; P = .16) and were more likely to have a clinically targetable variant (28.1% vs 0%; difference, 28.1%; 95% CI, 11.2%-40.2%; P = .03). In 14 participants with clinical data available, those with stage III/IV EHE were more likely to exhibit a secondary pathogenic genomic variant (80% vs 0%; difference, 80%; 95% CI, 55.2%-100%; P = .006). Participants with stage III/IV EHE were diagnosed at an older age (mean [SD] age, 54.6 [14.1] years vs 31.7 [16.0] years; P = .05) and had elevated WWTR1-CAMTA1 fusion expression that was not statistically significant (mean [SD] expression, 677 [706] copies vs 231 [213] copies; P = .20). Conclusions and Relevance: Although EHE exhibits few secondary genomic variants, presence of key secondary variants may be prognostic for aggressive EHE. Further research is needed to confirm this finding and determine whether more intensive upfront treatment is necessary for these patients.

AB - Importance: Epithelioid hemangioendothelioma (EHE) is a rare, malignant vascular sarcoma characterized in most cases by a WWTR1-CAMTA1 fusion. The clinical course of EHE exhibits a dual nature. The condition is often indolent but can rapidly grow and metastasize unpredictably. No biomarkers to date are available to predict this phenotype. The hypothesis of this study was that better defining the genomic landscape of EHE using next-generation sequencing could offer additional therapies and insight into clinical outcomes. Objective: To characterize secondary EHE genomic alterations and their association with clinical outcomes. Design, Setting, and Participants: Multicenter, cross-sectional, retrospective study of next-generation sequencing results collected from participants diagnosed with EHE. Data were abstracted between May 1, 2013, and May 31, 2019. This analysis was conducted from January through June 2019. Summary genomic data were provided by commercial genomic testing companies. Main Outcomes and Measures: Presence or absence of secondary pathogenic genomic variants and their association with disease stage and clinical features. Results: A total of 49 participants with EHE were assessed for the presence or absence of secondary genomic variants. Of these, 32 (65.3%) were female; the mean (SD) age at diagnosis was 49.9 (18.3) years (range, 11-81 years). In all, 46 participants (93.9%) had confirmed WWTR1-CAMTA1 fusion; 26 participants (57.1%) exhibited a pathogenic genomic variant secondary to the WWTR1-CAMTA1 fusion; and 9 participants (18.4%) exhibited potentially targetable genomic variants. Commonly altered genes included CDKN2A/B, RB1, APC, and FANCA. Participants older than 45 years at diagnosis had an increased prevalence of secondary genomic variants that was not statistically significant (65.6% vs 38.5%; difference, 27.1%; 95% CI, -3.5% to 58.0%; P = .16) and were more likely to have a clinically targetable variant (28.1% vs 0%; difference, 28.1%; 95% CI, 11.2%-40.2%; P = .03). In 14 participants with clinical data available, those with stage III/IV EHE were more likely to exhibit a secondary pathogenic genomic variant (80% vs 0%; difference, 80%; 95% CI, 55.2%-100%; P = .006). Participants with stage III/IV EHE were diagnosed at an older age (mean [SD] age, 54.6 [14.1] years vs 31.7 [16.0] years; P = .05) and had elevated WWTR1-CAMTA1 fusion expression that was not statistically significant (mean [SD] expression, 677 [706] copies vs 231 [213] copies; P = .20). Conclusions and Relevance: Although EHE exhibits few secondary genomic variants, presence of key secondary variants may be prognostic for aggressive EHE. Further research is needed to confirm this finding and determine whether more intensive upfront treatment is necessary for these patients.

UR - http://www.scopus.com/inward/record.url?scp=85072847654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072847654&partnerID=8YFLogxK

U2 - 10.1001/jamanetworkopen.2019.12416

DO - 10.1001/jamanetworkopen.2019.12416

M3 - Article

C2 - 31577358

AN - SCOPUS:85072847654

VL - 2

SP - e1912416

JO - JAMA network open

JF - JAMA network open

SN - 2574-3805

IS - 10

ER -